A Randomized, Double-Blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)

Trial Profile

A Randomized, Double-Blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs Brivanib alaninate (Primary)
  • Indications Liver cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms BRISK-TA
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 08 Jun 2017 Planned End Date changed from 1 Dec 2015 to 31 Jan 2018.
    • 09 Apr 2015 Planned End Date changed from 1 Mar 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 03 Mar 2015 Planned End Date changed from 1 Sep 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top